A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
Chao Liu,1 Hong Lu,2 Fei Yuan,1 Wei-Li Chen,1 Hong-Rong Xu,1 Hui Li,1 Cheng-Pang Hsu,3 Ogo Egbuna,3 Jihua Wu,2 Clapton Dias,3 Bassam Abosaleem,3 Jitesh Rana,3 Maria Laura Monsalvo,3 Xue-Ning Li,1 Zhigang Yu4 1Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/331de057614a45afb696e32413c77748 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:331de057614a45afb696e32413c77748 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:331de057614a45afb696e32413c777482021-12-02T04:44:52ZA Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects1179-1438https://doaj.org/article/331de057614a45afb696e32413c777482019-10-01T00:00:00Zhttps://www.dovepress.com/a-phase-1-randomized-double-blind-single-dose-placebo-controlled-safet-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Chao Liu,1 Hong Lu,2 Fei Yuan,1 Wei-Li Chen,1 Hong-Rong Xu,1 Hui Li,1 Cheng-Pang Hsu,3 Ogo Egbuna,3 Jihua Wu,2 Clapton Dias,3 Bassam Abosaleem,3 Jitesh Rana,3 Maria Laura Monsalvo,3 Xue-Ning Li,1 Zhigang Yu4 1Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Clinical Pharmacology and Early Development, Amgen China R & D Center, Shanghai, People’s Republic of China; 3Research & Development, Amgen Inc., Thousand Oaks, CA, USA; 4Clinical Development, Amgen China R & D Center, Shanghai, People’s Republic of ChinaCorrespondence: Xue-Ning LiDepartment of Clinical Pharmacology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, People’s Republic of ChinaTel +86 21 6026 7666Email li.xuening@zs-hospital.sh.cnZhigang YuResearch & Development, Amgen Inc., Thousand Oaks, CA 91320, USATel +1 805 447-9384Email zhigangy@amgen.comPurpose: Evolocumab is a human monoclonal antibody that reduces circulating low-density lipoprotein cholesterol (LDL-C) by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Data on evolocumab pharmacokinetics and pharmacodynamics are derived mostly from Caucasian populations. The objectives of this study were to characterize the single-dose pharmacokinetic and pharmacodynamic parameters, safety, and tolerability of evolocumab in healthy Chinese subjects.Subjects and methods: This was a phase 1, randomized, double-blind, placebo-controlled study (CTR20150465). Two parallel cohorts were randomized 5:1 to receive single subcutaneous injections of either evolocumab (140 mg or 420 mg) or placebo. Pharmacokinetics, pharmacodynamics, and safety were evaluated through day 85. The primary endpoints were maximum concentration (Cmax) and area under the drug concentration–time curve from time 0 to time of last quantifiable concentration (AUClast).Results: Thirty-six men (median age 26) were enrolled to receive evolocumab 140 mg (n=15), evolocumab 420 mg (n=15), or placebo (n=6). After 140 mg and 420 mg evolocumab, mean (SD) Cmax was 13.8 (3.6 μg/mL and 67.6 (15.2) μg/mL, respectively, and mean (SD) AUClast was 166 (55) day·μg/mL and 1110 (274) day·μg/mL, respectively. LDL-C declined reversibly, with reductions of 70% at 140 mg and 71% at 420 mg. Maximum effects on LDL-C and PCSK9 levels were reached by day 15 and 24 hrs, respectively, at 140 mg, and by day 22 and 4 hrs, respectively, at 420 mg. No serious adverse events occurred and the overall incidence of treatment-emergent adverse events was similar for evolocumab and placebo: 26.7% (140 mg) and 33.3% (placebo); 66.7% (420 mg) and 66.7% (placebo).Conclusion: In this population of healthy Chinese subjects, single 140 mg and 420 mg doses of evolocumab exhibited nonlinear kinetics and more than dose-proportional increases in exposure, were associated with up to 71% reduction in LDL-C, and demonstrated a safety profile similar to placebo.Keywords: cardiovascular disease, homozygous familial hypercholesterolemia, PCSK9 inhibitors, monoclonal antibodies, ethnic sensitivityLiu CLu HYuan FChen WLXu HRLi HHsu CPEgbuna OWu JDias CAbosaleem BRana JMonsalvo MLLi XNYu ZDove Medical Pressarticlecardiovascular diseasehomozygous familial hypercholesterolemiaPCSK9 inhibitorsmonoclonal antibodiesethnic sensitivityTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 11, Pp 145-153 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
cardiovascular disease homozygous familial hypercholesterolemia PCSK9 inhibitors monoclonal antibodies ethnic sensitivity Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
cardiovascular disease homozygous familial hypercholesterolemia PCSK9 inhibitors monoclonal antibodies ethnic sensitivity Therapeutics. Pharmacology RM1-950 Liu C Lu H Yuan F Chen WL Xu HR Li H Hsu CP Egbuna O Wu J Dias C Abosaleem B Rana J Monsalvo ML Li XN Yu Z A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects |
| description |
Chao Liu,1 Hong Lu,2 Fei Yuan,1 Wei-Li Chen,1 Hong-Rong Xu,1 Hui Li,1 Cheng-Pang Hsu,3 Ogo Egbuna,3 Jihua Wu,2 Clapton Dias,3 Bassam Abosaleem,3 Jitesh Rana,3 Maria Laura Monsalvo,3 Xue-Ning Li,1 Zhigang Yu4 1Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Clinical Pharmacology and Early Development, Amgen China R & D Center, Shanghai, People’s Republic of China; 3Research & Development, Amgen Inc., Thousand Oaks, CA, USA; 4Clinical Development, Amgen China R & D Center, Shanghai, People’s Republic of ChinaCorrespondence: Xue-Ning LiDepartment of Clinical Pharmacology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, People’s Republic of ChinaTel +86 21 6026 7666Email li.xuening@zs-hospital.sh.cnZhigang YuResearch & Development, Amgen Inc., Thousand Oaks, CA 91320, USATel +1 805 447-9384Email zhigangy@amgen.comPurpose: Evolocumab is a human monoclonal antibody that reduces circulating low-density lipoprotein cholesterol (LDL-C) by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Data on evolocumab pharmacokinetics and pharmacodynamics are derived mostly from Caucasian populations. The objectives of this study were to characterize the single-dose pharmacokinetic and pharmacodynamic parameters, safety, and tolerability of evolocumab in healthy Chinese subjects.Subjects and methods: This was a phase 1, randomized, double-blind, placebo-controlled study (CTR20150465). Two parallel cohorts were randomized 5:1 to receive single subcutaneous injections of either evolocumab (140 mg or 420 mg) or placebo. Pharmacokinetics, pharmacodynamics, and safety were evaluated through day 85. The primary endpoints were maximum concentration (Cmax) and area under the drug concentration–time curve from time 0 to time of last quantifiable concentration (AUClast).Results: Thirty-six men (median age 26) were enrolled to receive evolocumab 140 mg (n=15), evolocumab 420 mg (n=15), or placebo (n=6). After 140 mg and 420 mg evolocumab, mean (SD) Cmax was 13.8 (3.6 μg/mL and 67.6 (15.2) μg/mL, respectively, and mean (SD) AUClast was 166 (55) day·μg/mL and 1110 (274) day·μg/mL, respectively. LDL-C declined reversibly, with reductions of 70% at 140 mg and 71% at 420 mg. Maximum effects on LDL-C and PCSK9 levels were reached by day 15 and 24 hrs, respectively, at 140 mg, and by day 22 and 4 hrs, respectively, at 420 mg. No serious adverse events occurred and the overall incidence of treatment-emergent adverse events was similar for evolocumab and placebo: 26.7% (140 mg) and 33.3% (placebo); 66.7% (420 mg) and 66.7% (placebo).Conclusion: In this population of healthy Chinese subjects, single 140 mg and 420 mg doses of evolocumab exhibited nonlinear kinetics and more than dose-proportional increases in exposure, were associated with up to 71% reduction in LDL-C, and demonstrated a safety profile similar to placebo.Keywords: cardiovascular disease, homozygous familial hypercholesterolemia, PCSK9 inhibitors, monoclonal antibodies, ethnic sensitivity |
| format |
article |
| author |
Liu C Lu H Yuan F Chen WL Xu HR Li H Hsu CP Egbuna O Wu J Dias C Abosaleem B Rana J Monsalvo ML Li XN Yu Z |
| author_facet |
Liu C Lu H Yuan F Chen WL Xu HR Li H Hsu CP Egbuna O Wu J Dias C Abosaleem B Rana J Monsalvo ML Li XN Yu Z |
| author_sort |
Liu C |
| title |
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects |
| title_short |
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects |
| title_full |
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects |
| title_fullStr |
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects |
| title_full_unstemmed |
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects |
| title_sort |
phase 1, randomized, double-blind, single-dose, placebo-controlled safety, tolerability, and pharmacokinetic/pharmacodynamic study of evolocumab in healthy chinese subjects |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/331de057614a45afb696e32413c77748 |
| work_keys_str_mv |
AT liuc aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT luh aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT yuanf aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT chenwl aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT xuhr aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT lih aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT hsucp aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT egbunao aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT wuj aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT diasc aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT abosaleemb aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT ranaj aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT monsalvoml aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT lixn aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT yuz aphase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT liuc phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT luh phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT yuanf phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT chenwl phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT xuhr phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT lih phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT hsucp phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT egbunao phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT wuj phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT diasc phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT abosaleemb phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT ranaj phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT monsalvoml phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT lixn phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects AT yuz phase1randomizeddoubleblindsingledoseplacebocontrolledsafetytolerabilityandpharmacokineticpharmacodynamicstudyofevolocumabinhealthychinesesubjects |
| _version_ |
1718401080127127552 |